Nationwide butter recall in US as FDA issues urgent health warning to customers. Check details
Issuing the second-highest risk warning, the US Food and Drug Administration (FDA) has recalled butter across the nation due to a potential undeclared allergen. Based in Missouri, Bunge North America Inc., a voluntary recall of 64,800 pounds of its NH European Style Butter Blend on July 14 was initiated. This is because milk may have not have been listed on the product, reports NewsWeek. The FDA later issued a Class II risk classification for the recall on Thursday.
The FDA considers Class II recalls to be situations 'in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.' A Class II risk classification (one of three) refers to a situation in which the "use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote," according to the FDA.
ALSO READ: Tropical Storm Gil strengthens to become hurricane, urgent alert issued for Hawaii, California travellers
As defined in the law, milk is one of the nine major food allergens. The other items include eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, soybeans, and sesame. Allergic reactions vary in severity from mild symptoms, such as hives and lip swelling, to life-threatening complications, such as anaphylaxis, that may include fatal respiratory problems.
The recalled item is NH European Style Butter Blend, totaling 64,800 pounds.UPC Code: 1 00 78684 73961 2Lot Code: 5064036503Packaging: White paperboard cases, each containing 36 blocks.The affected cases were distributed to 12 distribution centers across the United States and one center in the Dominican Republic.
ALSO READ: Trading and cooking event update: How to make cooking recipe in Grow a Garden
The FDA, on its website: "People with food allergies should read labels and avoid the foods they are allergic to. The law requires that food labels identify the food source of all major food allergens used to make the food."
The Mayo Clinic, on its website: "Milk allergy is an atypical immune system response to milk and products containing milk. It's one of the most common food allergies in children. Cow's milk is the usual cause of milk allergy, but milk from sheep, goats, buffalo and other mammals also can cause a reaction.
ALSO READ: Sydney Sweeney and her American Eagle ad campaign face social media storm: Story in 10 points
"An allergic reaction usually occurs soon after you or your child consumes milk. Signs and symptoms of milk allergy range from mild to severe and can include wheezing, vomiting, hives and digestive problems. Milk allergy can also cause anaphylaxis — a severe, life-threatening reaction."Dr. Sebastian Lighvani, director of New York Allergy & Asthma PLLC, previously told Newsweek: "Every three minutes in the United States, someone ends up in an emergency room because of an allergic reaction after accidental ingestion of food. So even when we try hard, these reactions are happening. And if you look at the incidence of anaphylaxis, it has skyrocketed in the last five, 10, 20 years. And in the U.S., there's like a 300 to 400 percent increase in the rates of anaphylaxis to foods."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
2 hours ago
- Economic Times
Trump says he's cut drug prices by up to 1,500%. That's not possible
Synopsis Donald Trump claimed significant drug price cuts, even up to 1500%. Experts refute this, stating such cuts are impossible. They suggest it would mean people are paid to take medicine. The White House defended Trump, citing price differences with other nations. Trump also mentioned future price drops. Some drugmakers are open to cuts. AP Days after he sent letters instructing top pharmaceutical manufacturers to use a "most favored nation" pricing model for prescription drugs, President Donald Trump told reporters on Sunday that he had cut costs by up to 1,500%. But Trump's grandiose claim is mathematically impossible. Here's a closer look at the facts. TRUMP: "You know, we've cut drug prices by 1,200, 1,300, 1,400, 1,500%. I don't mean 50%, I mean 14 - 1,500%." THE FACTS: This is false. Cutting drug prices by more than 100% would theoretically mean that people are being paid to take medications. The Trump administration has taken steps to lower prescription drug prices, but experts say there's no indication costs have seen such a massive drop. Geoffrey Joyce, director of health policy at the University of Southern California's Schaeffer Center, called Trump's claim "total fiction" made up by the Republican president. He agreed that it would amount to drug companies paying customers, rather than the other way around. "I find it really difficult to translate those numbers into some actual estimates that patients would see at the pharmacy counter," said Mariana Socal, an associate professor of health policy and management at Johns Hopkins University who studies the U.S. pharmaceutical market. She added that Trump's math is "really hard to follow." Asked what Trump was using to back up his claim, White House spokesman Kush Desai said: "It's an objective fact that Americans are paying exponentially more for the same exact drugs as people in other developed countries pay, and it's an objective fact that no other Administration has done more to rectify this unfair burden for the American people." The White House provided a chart of price differentials for drugs in the U.S. and comparable countries, but did not offer any other evidence. On Sunday, Trump also described cuts to drug prices as a future development, not that already happened. "So we'll be dropping drug prices," he said. "It will start over the next two to three months by 1,200, 1,300 and even 1,400%." Prices for most prescription drugs - unbranded generics are the exception - are higher in the U.S. than they are in other high-income countries. This is in large part due to the way drug prices are negotiated in the United States. Trump made his recent appeal in letters to 17 pharmaceutical manufacturers, the White House announced last week. He asked them to reduce costs in the U.S. by matching the lowest prices of prescriptions drugs in other comparably developed countries. Some drugmakers have since indicated that they are open to cutting costs. This move follows an executive order Trump signed in May setting a 30-day deadline for drugmakers to electively lower prices in the U.S. or face new limits in the future over what the government will pay. The federal government has the most power to shape the price it pays for drugs covered by Medicare and Medicaid. It's unclear what - if any - impact the Trump administration's efforts will have on millions of Americans who have private health insurance. Socal pointed out that if drug manufacturers had cut costs to the extent Trump claims, they would be shouting it from the rooftops, especially given the heat they've taken over the years for their pricing practices. "My expectation would be that they would make announcements - public announcements - and that those announcements would come way in advance of the actual effective dates when those price cuts would come into effect," she said. Joyce agreed that there has been no indication of a substantial cut. "Not at all, not at all, none whatsoever," he said. "And let alone 1,500."
Time of India
5 hours ago
- Time of India
Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?
Why did Hims & Hers stock fall after earnings? Live Events Current Price : $63.35 : $63.35 Day Range : $54.82 – $65.54 : $54.82 – $65.54 Open : $64.00 : $64.00 Market Cap: $6.56 Billion P/E Ratio : 39.93 : 39.93 Volume: 35.5M Earnings beat estimates, but Wall Street stays cautious Is the GLP‑1 weight-loss business at risk? Regulatory uncertainty : With the FDA rolling back flexibility on compounded versions of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. : With the FDA rolling back flexibility on of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. Legal challenges : The company recently ended its supply relationship with Novo Nordisk , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. : The company recently ended its supply relationship with , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. Competitive pressure: Big players like Eli Lilly and Novo Nordisk are dominating the branded drug market, making it harder for telehealth companies offering generics to compete on pricing and trust. Hims keeps full-year guidance intact—thanks to international expansion Subscriber growth remains strong despite volatility What investors should watch going forward Future of compounded GLP-1s: Regulatory and legal outcomes could limit Hims' ability to sell compounded semaglutide at scale. Profitability trends: Will margins hold up as more competition floods the market and Hims scales its personalized offerings? Subscriber growth and retention: Continued engagement in non-weight loss categories will be key to long-term stability. Zava integration: The success or failure of this acquisition could make or break Hims' international ambitions. Hims still growing, but cracks are showing FAQs: (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Hims & Hers Health (NYSE: HIMS), the fast-growing telehealth company known for its personalized care plans and buzzy entry into the weight-loss market, saw its stock drop by over 11% after reporting second-quarter 2025 earnings. While revenue jumped 73% year-over-year, the company missed Wall Street expectations and posted its first-ever, raising questions about the future of itsDespite its rapid annual growth, Hims & Hers posted, missing the analyst estimate of. The real concern? Revenue dropped from, marking the first quarter-over-quarter decline since the company went stock currently trades at, regaining some ground after hitting an intraday low of. Despite opening at, it remains volatile, with an intraday high ofThe market reacted sharply to the company's revenue miss—$544.8 million vs. $552 million expected—even though earnings per share beat expectations and subscriber numbers remained strong. Most of the company's revenue stemmed from its GLP-1-based obesity and diabetes treatments, a booming but increasingly scrutinized business regulatory pressures, lawsuits from Novo Nordisk, and tighter FDA rules on compounded semaglutide, Hims faces headwinds in its fastest-growing segment. However, with a market cap of over $6.5 billion, a P/E ratio of 39.93, and forward-looking confidence via its Zava acquisition, the company is still betting big on growth in both the U.S. and were caught off guard, as the slowdown came amid soaring demand forlike semaglutide, a compound similar to the active ingredient in Wegovy and the profit front, Hims reported an adjusted EPS of $0.19, beating the Street's expectation of $0.15. However, the revenue miss overshadowed this earnings appeared more concerned about the underlying business momentum, particularly in the obesity treatment space, which has been a major driver of Hims' recent biggest growth story in recent quarters has been its expansion into GLP-1 weight-loss treatments, which brought in around $190 million in Q2 alone. However, a few red flags have emerged:Despite the Q2 shortfall, Hims & Hers stuck to its full-year outlook. The company reaffirmed its 2025 guidance of $2.3 billion to $2.4 billion in revenue and $295 million to $335 million in adjusted EBITDA.A big reason? The Zava acquisition, a European telehealth platform, which is expected to contribute around $50 million in new revenue this year. This suggests Hims is betting heavily on international growth to offset some of its domestic bright spot in the report was Hims' growing subscriber base. The company now serves over 2.4 million active subscribers, with nearly 70% enrolled in personalized treatment plans that span weight loss, hair care, sexual health, and mental Andrew Dudum emphasized that the company is leaning deeper into its long-term strategy of personalized digital healthcare, aiming to build loyalty and customer lifetime value across multiple product you're following Hims & Hers stock or investing in telehealth companies focused on the obesity drug boom, here are four key things to monitor:Hims & Hers Health has come a long way as a digital-first wellness brand with a bold strategy around weight-loss drugs and personalized healthcare. But the 11% stock drop shows investor sentiment is shifting, especially as its flagship obesity business faces regulatory hurdles and supply now, the company's strong year-over-year growth and firm 2025 guidance offer some reassurance. But with rising competition, tighter FDA rules, and legal pressure, Hims will need to prove that its success isn't just tied to a single product wave—but a durable, trusted digital care company missed revenue estimates and saw its first-ever sequential drop in due to FDA scrutiny and legal issues around compounded semaglutide.
Time of India
6 hours ago
- Time of India
Clear labelling a must for paneer substitutes: FDA
Mumbai: The firmer variant of paneer increasingly used in institutional kitchens is not traditional milk-based paneer, but a substitute known as analogue paneer. In response to consumer complaints about misleading substitutions, the food and drugs administration (FDA) has mandated that establishments using this product must clearly display notices on premises, menus, or packaging, disclosing its composition. Although the use of cheese analogues in the food service sector has been legally permitted since 2021, FDA officials have raised concerns over their use as direct substitutes for paneer. These concerns stem from differences in their physicochemical properties and potential health implications. Hospitality sector representatives, including members of the AHAR (Association of Hotels and Restaurants) and HRAWI (Hotel and Restaurant Association of Western India), confirmed that many establishments have already implemented the required labelling protocols. Pradeep Shetty, owner of Maharaja Catering and spokesperson for HRAWI, said analogue paneer is cheaper to produce due to its use of alternative ingredients, but "menu disclosures are essential". Sudhakar Shetty, restaurateur and president of AHAR, said many major food chains are complying with the regulation, though wider public awareness is still lacking. Meanwhile, the Centre is reviewing a regulatory proposal to permit the addition of food-grade colouring agents to analogue paneer to enable easy visual differentiation from traditional paneer. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Jennifer Garner's sweet photo on sprawling family farm gets fans talking Watch More Undo You Can Also Check: Mumbai AQI | Weather in Mumbai | Bank Holidays in Mumbai | Public Holidays in Mumbai "Nutritionally, traditional paneer, produced by curdling milk, contains 18-20 grams of high-quality, complete protein per 100 grams, providing all nine essential amino acids necessary for muscle synthesis, tissue repair and metabolic functions," explained Rajesh Bothra, a Navi Mumbai-based nutritionist and gym trainer. "In contrast, cheese analogues typically contain only 7-10 grams of protein per 100 grams, often derived from plant sources that may lack a full amino acid profile unless specially fortified. " Nemaram Agarwal of Rajlaxmi Dairy in Powai said high consumer demand and limited supply have led some dairies to use powdered milk or even lower-quality analogue substitutes.
